Kent Lake Capital’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

Kent Lake Capital’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-36,280	Closed	-$63K	–	35
2021 Q2	$63K	Hold	36,280	–	–	0.02%	28
2021 Q1	$49K	Buy	+36,280	New	+$67.3K	0.02%	30

Other funds holding STLNW

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

JP Morgan Chase

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Union Square Park Capital Management New York $176M AUM 51.52% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Kent Lake Capital's STLNW Position: Q3 2021 in Review

Kent Lake Capital sold out of Starling Oncology, Inc. Warrant (STLNW) in Q3 2021, closing a stake of 36,280 shares — an estimated $63K sold.

Kent Lake Capital first reported a position in STLNW in Q1 2021 and held it in 2 quarters. The position peaked at $63K in Q2 2021. 21 funds tracked by Wall St. Rank hold STLNW as of Q3 2021.

Kent Lake Capital reported no remaining Starling Oncology, Inc. Warrant position as of Q3 2021 after selling out during the quarter.
Kent Lake Capital sold 36,280 Starling Oncology, Inc. Warrant shares in Q3 2021, an estimated $63K.
Kent Lake Capital first reported a position in Starling Oncology, Inc. Warrant in Q1 2021 and held it in 2 quarters.
Kent Lake Capital's Starling Oncology, Inc. Warrant position peaked at $63K in Q2 2021.
21 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q3 2021.

Based on Kent Lake Capital's 13F filing for Q3 2021, filed 15 Nov 2021.